Magellan Bioanalytics, a Brigham Young University (BYU) spinoff, is dedicated to lowering healthcare costs and improving patient care by predicting patient response to therapeutics by analyzing individuals' biomarker profiles. Currently, the company' team is working with healthcare partners to validate their analytics for immuno-oncology therapies and guide treatment decisions. Magellan Bioanalytics' biomarker profiling platform analyzes differential expression of 30-35,000 low abundance biomarker species in serum samples. Furthermore, it has a 100% success rate in identifying biomarkers from a variety of disease states, ranging from women's health (preeclampsia, endometriosis) to Alzheimer's to oncology.

Magellan Bioanalytics generates human health data from analysis of the 'hidden proteome', a fraction of human serum that contains more than 30,000 potential biomarkers. Magellan Bioanalytics proprietary technology has successfully identified biomarkers that predict or stage disease in various indications, from breast cancer (lat. Carcinoma) to Alzheimer's (lat. morbus Alzheimerianus).

According to the World Health Organization, cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Approximately 70% of deaths from cancer occur in low- and middle-income countries. An important moment that affects the percentage of cured patients is not only an early diagnosis, but also the ability to predict the response to the therapy of the patient. This enables doctors to take the necessary measures in order to correct the therapy to improve its effectiveness.

However, current Magellan Bioanalytics' partnerships are designed to identify markers that predict patient response to cancer immunotherapy. In addition, the company is actively looking at additional partners to leverage the developed technology in other areas of human health.